Could one pill a day make HIV treatment easier? a new study asks patients

NCT ID NCT01322932

Completed Disease control Sponsor: Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study surveys HIV-positive adults who switch from taking two or three pills to a single pill containing the same three medicines (tenofovir, emtricitabine, and efavirenz). Researchers want to know if the simpler regimen improves how well patients take their medication, how they feel about side effects, and their overall satisfaction. The study follows 95 participants in Switzerland and uses questionnaires and medical records to track outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a single-pill combination of tenofovir, emtricitabine, and efavirenz
What this could lead to: If successful, this could show that a single-pill regimen improves adherence and satisfaction for people with HIV, making daily treatment simpler.
What could go wrong: This is a small survey study, so results may not apply to all HIV patients. It does not test a new drug, only a different way of taking existing ones.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease Medication Adherence Patient Satisfaction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTION

Contacts and locations

Show contact details

Locations

Centre Hospitalier Universitaire Vaudois et Policlinique Medicale Universitaire

Lausanne, Canton of Vaud, 1011, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.